Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, brain ischemia, a head trauma injury, a spinal trauma injury, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.

Abstract: The invention describes the synthesis and use of photoactivated (or caged) fluorescent dyes. Upon illumination at less than about 400 nm the caged dyes release highly fluorescent, water soluble hydroxypyrenesulfonic acid dyes according to the following equation: ##STR1## X, Y, and Z are independently sulfonic acid, a sulfonic acid salt, a hydroxyl group, or hydrogen, with at least one of X, Y, and Z being a sulfonic acid or sulfonic acid salt. LINK is either an ether linkage or a carbonate linkage. BLOCK is a caging group whose photolysis results in liberation of a free hydroxypyrenesulfonic acid dye.The caged fluorescent dyes are useful for application in aqueous solutions, including fluids of biological origin. The caged dyes of the present invention are especially useful for flow tagging velocimetry.

Abstract: Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating psychosis are disclosed by administering to an animal in need of such treatment a compound having high affinity for the glycine binding site, lacking PCP side effects and which crosses the blood brain barrier of the animal.Also disclosed are novel 1,4-dihydroquinoxaline-2,3-diones, and pharmaceutical compositions thereof. Also disclosed are highly soluble ammonium salts of 1,4-dihydroquinoxaline-2,3-diones.

Abstract: Prophylactic and therapeutic applications of peroxidases for the manufacture of medicaments for the treatment and prevention and treatment of enveloped virus infections and, in particular, of herpes simplex and immunodeficiency virus infections. The medicaments include a peroxidase, a substrate and a peroxide in a pharmaceutically acceptable carrier. Peroxidases of the medicaments include lactoperoxidase and myeloperoxidase. The medicaments are formulated with a pharmaceutically acceptable carrier for topical, oral and injectable administration to individuals in need thereof.

Abstract: A compound of formula (I): ##STR1## in which: R.sub.1 represents substituted or unsubstituted phenyl or (C.sub.3 -C.sub.7) cycloalkyl,R.sub.2 represents trifluoromethyl or (C.sub.3 -C.sub.4) cycloalkyl,A represents --CH.sub.2 --, --CH.dbd.N--, .dbd.N-- or --NH--,R.sub.3 and R.sub.4, which may be identical or different, represent hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl or, with the nitrogen atoms to which they are attached, form a 5- or 6-membered heterocycle,R represents either hydrogen in the case where A=--CH.sub.2 --, --CH.dbd.N-- or --NH--, or a bond of the group A when the latter is equal to .dbd.N--,its enantiomers and epimers as well as its addition salts with a pharmaceutically acceptable acid.Medicine products.

Abstract: Isophorone diamine is prepared from isophorone nitrile by imination using a supported heteropoly acid catalyst to form the ketimine followed by the reduction of the ketimine to form the diamine.

Abstract: Methods and compositions utilizing 2-amino-5-thiazolyl thiocyanate compounds and their derivatives for the control of soilborne fungi and disease caused thereby are described.

Abstract: This invention provides a stereospecific process for the synthesis of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, a key intermediate in the synthesis of duloxetine.

Abstract: A process is disclosed for producing a substituted ethylenediamine, the process comprising reacting an oxazolidinone with a secondary amine or an alkanolamine. The process includes, in one aspect, reacting precursors of the oxazolidinone in situ.

Abstract: N-Phenylsulfonyl-N'-pyrimidinyl-,-N'-triazinyl- and-N'-triazolylureas and -thioureas of formula I ##STR1## in which X is oxygen, sulfur, SO or SO.sub.2 ; W is oxygen or sulfur, R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen, fluorine, chlorine, bromine, iodine, (X).sub.n R.sub.3, NO.sub.2, NR.sub.4 R.sub.5, --C.tbd.CR.sub.6, ##STR2## or cyano; n is the number 0 or 1; R.sub.3 is C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkyl which is substituted by 1-4 halogen atoms, C.sub.1 -C.sub.3 alkoxy or C.sub.1 -C.sub.3 alkylthio; or C.sub.2 -C.sub.4 alkenyl or C.sub.2 -C.sub.4 alkenyl which is substituted by 1-4 halogen atoms; R.sub.4 is hydrogen, CH.sub.3 O, CH.sub.3 CH.sub.2 O or C.sub.1 -C.sub.3 alkyl; R.sub.5 is hydrogen or C.sub.1 -C.sub.3 alkyl; R.sub.6 is hydrogen, methyl or ethyl; R.sub.7 is hydrogen or methyl; Z is ##STR3## E is methine or nitrogen; R.sub.8 is C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkoxy, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 haloalkylthio, C.sub.

Abstract: The reduction of the O-alkyl isomer content of 5-[N-(2-acetoxyethyl)acetoxyacetamido]-N,N'-bis(2,3-diacetoxypropyl)-2,4,6 -triiodoisophthalamide to thereby reduce and/or eliminate the production of impurities comparatively more difficult to remove during the purification of crude ioversol.

Abstract: Provided by the present invention is a process for the biocatalytic synthesis of optically pure sphingosines from achiral starting material. The stereoisomers of sphingosine are prepared from chiral arene diols using stereospecific reaction techniques to obtain the desired sphingosine or derivative thereof.

Abstract: A modified natural clinoptilolite, produced by treating a natural clinoptilolite with a suitable mineral acid or with a suitable alkali and then with a suitable mineral acid, is used as a catalyst in a process for the conversion of methanol and ammonia to give a product containing at least 50% by weight of monomethylamine.

Abstract: The present invention is directed to the use of benzothiadiazide derivatives as nootropic agents to treat memory and learning disorders.

Abstract: Provided by the present invention is a process for the biocatalytic synthesis of optically pure sphingosines from achiral starting material. The stereoisomers of sphingosine are prepared from chiral arene diols using stereospecific reaction techniques to obtain the desired sphingosine or derivative thereof.

Abstract: A mixture of .beta.-sitosterol glucoside and .beta.-sitosterol is administered to persons for the modulation or control of immune responses. The two compounds may be added in admixture or sequentially. Diseases such as viral and bacterial infections, autoimmune diseases, psoriasis, ezcema, asthma, cancer may be treated.

Abstract: A compound for controlling Take-all disease of plants by applying, preferably to the seed prior to planting, a fungicide of the formula ##STR1## wherein R.sup.2 is ethyl, iso-propyl, propyl or allyl; A is N(CH.sub.3).sub.1-n H.sub.n R.sup.5 or OR.sup.6 wherein n is 0 or 1, R.sup.5 is (CH.sub.3).sub.m (CH.sub.3 CH.sub.2).sub.3-m C, 1-methylcyclopentyl, 1-methylcyclohexyl or 2,3-dimethyl-2-butyl wherein m is 0, 1, 2 or 3 and R.sup.6 is independently R.sup.5 or 2,3,3-trimethyl-2-butyl;R.sup.3 is H or independently R.sup.4 ; andR.sup.4 is halo or CH.sub.3 ;with the proviso that when A is N(CH.sub.3).sub.1-n H.sub.n R.sup.5, if R.sup.3 is H and R.sup.5 is 1-methyl-1-cyclohexyl or (CH.sub.3).sub.m (CH.sub.2 CH.sub.3).sub.3-m C, where m is 0 or 3, or if R.sup.3 is halo and R.sup.5 is (CH.sub.3).sub.m (CH.sub.3 CH.sub.2).sub.3-m C, where m is 3, then R.sup.2 cannot be ethyl;and with the proviso that when A is OR.sup.6 then m is equal to or less than 2, and if R.sup.3 is H or halo and R.sup.

Abstract: The invention is antiobesity/antidiabetes beta-3 agonists of the formula: ##STR1## wherein Ar, X, R.sub.2, R.sub.3, Y and n are as defined in the specification.

Abstract: There are provided fungicidal thienyl- and furylpyrrole compounds of formula I ##STR1## Further provided are compositions and methods comprising those compounds for the protection of plants from fungal infestation and disease.

Abstract: Cyclohexanedione derivatives of the formula (I), ##STR1## wherein R.sup.1 is a C.sub.1 -C.sub.6 alkyl group, R.sup.2 is a C.sub.1 -C.sub.4 alkyl group, each of R.sup.3, R.sup.4 and R.sup.5 is independently hydrogen or a C.sub.1 -C.sub.4 alkyl group, and n is an integer of 0 to 2, or salts thereof exhibit high selectivity for corn, wheat and barley, and can control gramineous weeds and broad-leaved weeds at low dosages.